3.92 +0.07 (1.76%)
After hours: 4:11PM EDT
Previous Close | 4.00 |
Open | 4.00 |
Bid | 3.80 x 300 |
Ask | 4.20 x 400 |
Day's Range | 3.80 - 4.05 |
52 Week Range | 3.70 - 8.80 |
Volume | 162,952 |
Avg. Volume | 251,798 |
Market Cap | 79.969M |
Beta | 2.06 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.18 |
Earnings Date | May 12, 2017 - May 15, 2017 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.81 |
Cidara Therapeutics, Inc. , a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases to be held in Madrid, Spain, April 21-24, 2018.
Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms. Definitive Phase 1 QT clinical trial showed no cardiac abnormalities. SAN DIEGO, ...
Stock Monitor: BioTime Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Cidara Therapeutics, Inc. (NASDAQ: CDTX ). If ...
Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.
Shares of Cidara Therapeutics Inc. shot up 14% toward a 13-month high in premarket trade Monday, after the biotechnology company said its lead antifungal drug candidate met all of its primary objectives ...
Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections. Phase 3 studies for both treatment and prevention on track to ...
SAN DIEGO, March 08, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted ...
SAN DIEGO, March 01, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of Chrysa Mineo to the company’ ...
The San Diego-based company said it had a loss of 69 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
SAN DIEGO, Feb. 27, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full ...
WASHINGTON , Jan. 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today that Michael Dunne , M.D., Chief Scientific Officer of Iterum Therapeutics, has been appointed as Vice ...
SAN DIEGO, Jan. 29, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its ...
Cidara will be completing Phase II trials for antifungal candidate rezafungin this quarter, followed by Scynexis. If approved, the drugs will compete with Merck, Astellas, and Pfizer.
Q3 2017 Cidara Therapeutics Inc Earnings Call
The San Diego-based company said it had a loss of 73 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Cidara Therapeutics, Inc. (NASDAQ: CDTX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:05 PM Eastern ...